Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.

Ataru IgarashiBarnaby HuntLars WilkinsonJakob LangerRichard F Pollock

Published in: Advances in therapy (2020)

These findings suggest that once-weekly semaglutide is a cost-effective treatment option compared with once-weekly dulaglutide for patients with T2D in Japan. In the future, this finding should be extrapolated to traditional long-term cost-effectiveness analysis, using common outcomes such as quality-adjusted life years.

Keyphrases

current status
type diabetes
emergency department
quality improvement
skeletal muscle
weight loss
electronic health record